SRRA
NASDAQSierra Oncology Inc.
Latest news
25 items- NEWSCodexis Announces CEO Transition Effective August 9, 2022, John Nicols To Retire As President, CEO; Dr. Stephen Dilly Appointed By Board Of DirectorsDr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEO John Nicols to retire after ten years leading the transformation and growth of Codexis Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company's President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons after leading the company's transformation and subsequent growth for the last decade. Mr. Nicols will remain on Codexis' Board through the ann
- PRCodexis Announces CEO Transition Effective August 9, 2022Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY, Calif., July 18, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that its Board of Directors appointed Dr. Stephen Dilly, former CEO of Sierra Oncology, Inc. and current Codexis Board member, as the company's President and CEO, effective August 9, 2022. John Nicols will retire as President and CEO for family reasons after leading the company's transformation and subsequent growth for the last decad
- 13D/GSEC Form SC 13D/A filed by Sierra Oncology Inc. (Amendment)SC 13D/A - Sierra Oncology, Inc. (0001290149) (Subject)
- SECSEC Form 15-12G filed by Sierra Oncology Inc.15-12G - Sierra Oncology, Inc. (0001290149) (Filer)
- SECSEC Form EFFECT filed by Sierra Oncology Inc.EFFECT - Sierra Oncology, Inc. (0001290149) (Filer)
- SECSEC Form EFFECT filed by Sierra Oncology Inc.EFFECT - Sierra Oncology, Inc. (0001290149) (Filer)
- 13D/GSEC Form SC 13G/A filed by Sierra Oncology Inc. (Amendment)SC 13G/A - Sierra Oncology, Inc. (0001290149) (Subject)
- INSIDERSEC Form 4: Vivo Opportunity, Llc returned $183,123,160 worth of shares to the company (3,329,512 units at $55.00)4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- INSIDERSEC Form 4: Orbimed Advisors Llc returned $108,062,350 worth of shares to the company (1,964,770 units at $55.00)4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- INSIDERSEC Form 4: Ashiya Mona returned $108,062,350 worth of shares to the company (1,964,770 units at $55.00)4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- INSIDERSEC Form 4: Aggarwal Gaurav returned $150,471,915 worth of shares to the company (2,735,853 units at $55.00)4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- INSIDERSEC Form 4: Sinclair Andrew returned $72,276,985 worth of shares to the company (1,314,127 units at $55.00) (withholding obligation)4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- INSIDERSEC Form 4: Klencke Barbara returned $825,000 worth of shares to the company (15,000 units at $55.00), closing all direct ownership in the company4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- INSIDERSEC Form 4 filed by Jagpal Sukhi4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- INSIDERSEC Form 4 filed by Pelzer Robert4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- INSIDERSEC Form 4 filed by Cooper Jeffrey H4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- INSIDERSEC Form 4: Allen Andrew R returned $90,750 worth of shares to the company (1,650 units at $55.00), closing all direct ownership in the company4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- INSIDERSEC Form 4: Collard Craig A returned $742,500 worth of shares to the company (13,500 units at $55.00), closing all direct ownership in the company4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- INSIDERSEC Form 4: Dilly Stephen George returned $275,000 worth of shares to the company (5,000 units at $55.00), closing all direct ownership in the company4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- INSIDERSEC Form 4 filed by Thomson Mary Christina4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- INSIDERSEC Form 4 filed by Turner William D.4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- INSIDERSEC Form 4 filed by Norrett Kevin4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- INSIDERSEC Form 4 filed by Oliger Christy J.4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- INSIDERSEC Form 4 filed by Erbez Georgia4 - Sierra Oncology, Inc. (0001290149) (Issuer)
- SECSEC Form S-8 POS filed by Sierra Oncology Inc.S-8 POS - Sierra Oncology, Inc. (0001290149) (Filer)
SRRA FAQ
7 questionsWhat does Sierra Oncology Inc. do?
Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its...Where does SRRA stock trade?
Sierra Oncology Inc. (SRRA) is listed on NASDAQ.What sector and industry is SRRA in?
Sierra Oncology Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Sierra Oncology Inc. go public?
Sierra Oncology Inc. (SRRA) completed its IPO in 2015.What are analysts saying about SRRA?
Sierra Oncology Inc. has had 4 recent analyst actions on file. The most recent action was from HC Wainwright & Co.: Buy on 2022-01-31. Recent price targets range from $3300.00 to $3900.00.What companies are similar to SRRA?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SRRA side-by-side with any of them on Quantisnow.How can I track SRRA on Quantisnow?
Quantisnow aggregates Sierra Oncology Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SRRA to receive live email and push alerts on every new disclosure.